CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Sage Therapeutics, Inc. - SAGE CFD

21.77
2.06%
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.17
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

SAGE Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 21.33
Open* 21.54
1-Year Change* -48.1%
Day's Range* 21.48 - 22.1
52 wk Range 16.52-59.99
Average Volume (10 days) 1.19M
Average Volume (3 months) 18.40M
Market Cap 1.56B
P/E Ratio -100.00K
Shares Outstanding 60.03M
Revenue 11.35M
EPS -10.98
Dividend (Yield %) N/A
Beta 0.91
Next Earnings Date Feb 14, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 1, 2024 21.77 0.34 1.59% 21.43 22.11 21.39
Feb 29, 2024 21.33 -1.33 -5.87% 22.66 22.77 21.31
Feb 28, 2024 22.47 0.29 1.31% 22.18 22.71 21.81
Feb 27, 2024 22.63 -0.22 -0.96% 22.85 22.97 22.51
Feb 26, 2024 22.57 0.80 3.67% 21.77 22.60 21.75
Feb 23, 2024 21.92 -0.03 -0.14% 21.95 22.07 21.44
Feb 22, 2024 22.17 0.43 1.98% 21.74 22.53 21.19
Feb 21, 2024 22.14 0.16 0.73% 21.98 22.34 21.63
Feb 20, 2024 22.09 -0.73 -3.20% 22.82 23.08 21.98
Feb 16, 2024 23.12 -1.93 -7.70% 25.05 25.05 23.04
Feb 15, 2024 25.23 -0.42 -1.64% 25.65 25.95 25.05
Feb 14, 2024 25.54 0.66 2.65% 24.88 27.33 23.48
Feb 13, 2024 22.83 0.08 0.35% 22.75 23.67 22.59
Feb 12, 2024 23.77 0.44 1.89% 23.33 23.92 23.13
Feb 9, 2024 23.52 -0.15 -0.63% 23.67 24.11 23.15
Feb 8, 2024 23.61 -0.07 -0.30% 23.68 24.07 23.34
Feb 7, 2024 23.83 -0.66 -2.69% 24.49 24.49 23.62
Feb 6, 2024 24.65 0.85 3.57% 23.80 24.85 23.68
Feb 5, 2024 24.23 -0.04 -0.16% 24.27 24.41 23.68
Feb 2, 2024 24.69 -0.58 -2.30% 25.27 25.46 24.30

Sage Therapeutics, Inc. Events

Time (UTC) Country Event
Tuesday, March 5, 2024

Time (UTC)

19:50

Country

US

Event

SAGE Therapeutics Inc at TD Cowen Health Care Conference
SAGE Therapeutics Inc at TD Cowen Health Care Conference

Forecast

-

Previous

-
Tuesday, April 30, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 SAGE Therapeutics Inc Earnings Release
Q1 2024 SAGE Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Friday, June 14, 2024

Time (UTC)

12:30

Country

US

Event

SAGE Therapeutics Inc Annual Shareholders Meeting
SAGE Therapeutics Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 7.686 6.308 1114.2 6.868 90.273
Total Operating Expense 554.675 467.217 517.974 714.992 483.511
Selling/General/Admin. Expenses, Total 227.699 183.498 196.952 345.777 201.404
Research & Development 326.163 283.166 292.714 368.815 282.107
Operating Income -546.989 -460.909 596.226 -708.124 -393.238
Interest Income (Expense), Net Non-Operating 14.19 2.883 9.597 27.804 20.334
Other, Net 0.015 0.134 0.25 0.082 0.022
Net Income Before Taxes -532.784 -457.892 606.073 -680.238 -372.882
Net Income After Taxes -532.784 -457.892 606.073 -680.238 -372.882
Net Income Before Extra. Items -532.784 -457.892 606.073 -680.238 -372.882
Net Income -532.784 -457.892 606.073 -680.238 -372.882
Income Available to Common Excl. Extra. Items -532.784 -457.892 606.073 -680.238 -372.882
Income Available to Common Incl. Extra. Items -532.784 -457.892 606.073 -680.238 -372.882
Diluted Net Income -532.784 -457.892 606.073 -680.238 -372.882
Diluted Weighted Average Shares 59.3061 58.6702 53.0031 50.8338 46.1212
Diluted EPS Excluding Extraordinary Items -8.98363 -7.8045 11.4347 -13.3816 -8.08483
Diluted Normalized EPS -8.98363 -7.8045 11.9581 -13.3816 -8.08483
Total Extraordinary Items
Revenue 7.686 6.308 1114.2 6.868 90.273
Cost of Revenue, Total 0.813 0.553 0.565 0.4
Gross Profit 6.873 5.755 1113.64 6.468
Unusual Expense (Income) 0 0 27.743
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 2.474 3.294 2.865 1.739 1.501
Revenue 2.474 3.294 2.865 1.739 1.501
Cost of Revenue, Total 0.205 0.23 0.143 0.184 0.2
Gross Profit 2.269 3.064 2.722 1.555 1.301
Total Operating Expense 172.931 158.764 156.767 143.219 129.908
Selling/General/Admin. Expenses, Total 75.565 65.708 67.329 61.482 52.411
Research & Development 97.161 92.826 89.295 81.553 77.297
Operating Income -170.457 -155.47 -153.902 -141.48 -128.407
Interest Income (Expense), Net Non-Operating 10.173 8.83 6.793 4.127 2.102
Other, Net -0.041 -0.188 -0.037 0.03 0.045
Net Income Before Taxes -160.325 -146.828 -147.146 -137.323 -126.26
Net Income After Taxes -160.325 -146.828 -147.146 -137.323 -126.26
Net Income Before Extra. Items -160.325 -146.828 -147.146 -137.323 -126.26
Net Income -160.325 -146.828 -147.146 -137.323 -126.26
Income Available to Common Excl. Extra. Items -160.325 -146.828 -147.146 -137.323 -126.26
Income Available to Common Incl. Extra. Items -160.325 -146.828 -147.146 -137.323 -126.26
Diluted Net Income -160.325 -146.828 -147.146 -137.323 -126.26
Diluted Weighted Average Shares 59.7696 59.6741 59.4967 59.4281 59.2663
Diluted EPS Excluding Extraordinary Items -2.68238 -2.4605 -2.47318 -2.31074 -2.13038
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -2.68238 -2.4605 -2.47318 -2.31074 -2.13038
Unusual Expense (Income) 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 1336.98 1800.64 2122.37 1035.09 944.695
Cash and Short Term Investments 1272.49 1742.3 2099.55 1008.39 922.776
Cash & Equivalents 162.7 294.233 1661.08 126.705 190.943
Short Term Investments 1109.79 1448.06 438.467 881.688 731.833
Prepaid Expenses 50.826 39.841 22.821 26.7 21.919
Total Assets 1356.45 1825.29 2159.25 1084.15 952.705
Property/Plant/Equipment, Total - Net 13.43 19.125 31.819 42.897 5.643
Property/Plant/Equipment, Total - Gross 19.525 24.098 38.907 47.396 7.859
Accumulated Depreciation, Total -6.095 -4.973 -7.088 -4.499 -2.216
Other Long Term Assets, Total 6.039 5.52 5.057 6.16 2.367
Total Current Liabilities 99.259 85.193 67.204 112.128 86.03
Accounts Payable 18.95 10.45 3.691 15.266 34.036
Accrued Expenses 37.572 26.703 23.931 33.202 19.875
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 42.737 48.04 39.582 63.66 32.119
Total Liabilities 103.85 96.257 86.912 139.495 89.734
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 4.591 11.064 19.708 27.367 3.704
Total Equity 1252.6 1729.03 2072.33 944.655 862.971
Redeemable Preferred Stock 0 0 0 0
Common Stock 0.006 0.006 0.006 0.005 0.005
Additional Paid-In Capital 3291.37 3227.47 3109.81 2587.32 1827.02
Retained Earnings (Accumulated Deficit) -2028.17 -1495.39 -1037.49 -1643.57 -963.329
Treasury Stock - Common -0.4 -0.4 -0.4 -0.4 -0.211
Other Equity, Total -10.206 -2.66 0.415 1.295 -0.515
Total Liabilities & Shareholders’ Equity 1356.45 1825.29 2159.25 1084.15 952.705
Total Common Shares Outstanding 59.5091 58.937 58.3084 51.8772 46.8883
Total Receivables, Net 13.66 18.506
Accounts Receivable - Trade, Net 13.66 18.506
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 933.27 1064.03 1203.44 1336.98 1465.1
Cash and Short Term Investments 876.052 1002.62 1129.58 1272.49 1393.64
Cash & Equivalents 148.712 121.416 206.557 162.7 199.826
Short Term Investments 727.34 881.2 923.028 1109.79 1193.81
Total Receivables, Net 22.513 15.09 15.002 13.66 18.448
Accounts Receivable - Trade, Net 22.513 15.09 15.002 13.66 18.448
Prepaid Expenses 34.705 46.321 58.85 50.826 53.017
Total Assets 949.663 1082.29 1220.69 1356.45 1486.07
Property/Plant/Equipment, Total - Net 8.468 10.04 11.725 13.43 14.791
Property/Plant/Equipment, Total - Gross 19.525
Accumulated Depreciation, Total -6.095
Other Long Term Assets, Total 7.925 8.221 5.524 6.039 6.178
Total Current Liabilities 133.004 96.807 84.692 99.259 99.687
Accounts Payable 11.136 9.283 12.263 18.95 7.077
Accrued Expenses 45.985 27.789 18.369 37.572 28.299
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 75.883 59.735 54.06 42.737 64.311
Total Liabilities 133.004 97.912 87.557 103.85 105.951
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0 1.105 2.865 4.591 6.264
Total Equity 816.659 984.376 1133.13 1252.6 1380.12
Redeemable Preferred Stock 0 0 0 0
Common Stock 0.006 0.006 0.006 0.006 0.006
Additional Paid-In Capital 3357.74 3325.74 3313.61 3291.37 3276.42
Retained Earnings (Accumulated Deficit) -2536.95 -2335.32 -2175 -2028.17 -1881.02
Treasury Stock - Common -0.4 -0.4 -0.4 -0.4 -0.4
Other Equity, Total -3.735 -5.644 -5.088 -10.206 -14.883
Total Liabilities & Shareholders’ Equity 949.663 1082.29 1220.69 1356.45 1486.07
Total Common Shares Outstanding 59.8839 59.796 59.762 59.5091 59.4937
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -532.784 -457.892 606.073 -680.238 -372.882
Cash From Operating Activities -460.036 -378.182 664.28 -528.706 -260.671
Cash From Operating Activities 1.122 4.182 2.63 2.283 1.143
Non-Cash Items 65.955 94.034 95.306 142.591 91.856
Changes in Working Capital 5.671 -18.506 -39.729 6.658 19.212
Cash From Investing Activities 325.433 -1002.45 442.684 -143.156 -512.461
Capital Expenditures -0.937 -0.372 -0.345 -5.751 -2.86
Other Investing Cash Flow Items, Total 326.37 -1002.08 443.029 -137.405 -509.601
Cash From Financing Activities 3.07 13.334 426.762 607.624 659.358
Financing Cash Flow Items -0.043 -1.385 -2.503 -1.244
Issuance (Retirement) of Stock, Net 3.113 14.719 426.762 610.127 660.602
Net Change in Cash -131.533 -1367.3 1533.73 -64.238 -113.774
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -146.828 -532.784 -385.638 -248.315 -122.055
Cash From Operating Activities -153.682 -460.036 -333.104 -214.239 -107.8
Cash From Operating Activities 0.323 1.122 0.832 0.554 0.275
Non-Cash Items 16.83 65.955 52.076 37.849 20.897
Changes in Working Capital -24.007 5.671 -0.374 -4.327 -6.917
Cash From Investing Activities 194.867 325.433 235.656 124.704 -9.558
Other Investing Cash Flow Items, Total 195.092 326.37 236.311 124.995 -9.389
Cash From Financing Activities 2.672 3.07 3.041 1.812 1.799
Issuance (Retirement) of Stock, Net 3.301 3.113 3.08 1.836 1.799
Net Change in Cash 43.857 -131.533 -94.407 -87.723 -115.559
Capital Expenditures -0.225 -0.937 -0.655 -0.291 -0.169
Financing Cash Flow Items -0.629 -0.043 -0.039 -0.024
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Fidelity Management & Research Company LLC Investment Advisor 14.6778 8789617 1706204 2023-06-30 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 10.6266 6363630 649207 2023-06-30 LOW
Biogen Inc Corporation 10.4226 6241473 0 2023-03-31 HIGH
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 8.3815 5019202 53550 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.9624 3570538 -11550 2023-06-30 LOW
Bellevue Asset Management AG Investment Advisor 5.2007 3114375 24375 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 3.8393 2299140 -435233 2023-06-30 LOW
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 2.866 1716268 61568 2023-06-30 LOW
JP Morgan Asset Management Investment Advisor 1.857 1112064 291861 2023-06-30 LOW
Boxer Capital, L.L.C. Hedge Fund 1.8269 1094000 0 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.7827 1067545 27300 2023-06-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 1.7505 1048295 -829697 2023-06-30 LOW
DWS Investment GmbH Investment Advisor/Hedge Fund 1.6699 1000000 300000 2023-06-30 LOW
Palo Alto Investors LP Hedge Fund 1.4353 859517 0 2023-06-30 LOW
Lord, Abbett & Co. LLC Investment Advisor 1.382 827577 637244 2023-06-30 MED
Marshall Wace LLP Investment Advisor/Hedge Fund 1.3335 798548 -613381 2023-06-30 HIGH
Columbia Threadneedle Investments (US) Investment Advisor/Hedge Fund 1.0796 646495 -228289 2023-06-30 LOW
Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 1.0001 598918 592380 2023-06-30 LOW
Manulife Investment Management (North America) Limited Investment Advisor 0.9918 593938 -30733 2023-06-30 LOW
JPMorgan Asset Management U.K. Limited Investment Advisor/Hedge Fund 0.864 517402 26317 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Sage Therapeutic Company profile

About SAGE Therapeutics Inc

SAGE Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing medicines with debilitating disorders of the brain. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD), in adults. The Company's products also include ZULRESSO (Brexanolone) CIV Injection, Zuranolone (SAGE-217), SAGE-324 and SAGE-718. Its next advanced product candidate is SAGE-217, is an oral compound that is in Phase III clinical development in PPD and depressive disorder (MDD). Zuranolone is a neuroactive steroid that, like brexanolone, is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. SAGE-324 is a GABAA receptor positive allosteric modulator intended for chronic oral dosing and conducting a placebo-controlled Phase II clinical trial evaluating the safety and efficacy of SAGE-324 in the treatment of essential tremor.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, SAGE Therapeutics Inc revenues decreased 99% to $6.3M. Net loss totaled $457.9M vs. income of $606.1M. Revenues reflect Collaboration revenue decrease from $1.11B to $0K, Product decrease of 6% to $6.3M. Net loss reflects Stock-based Compensation in R&D increase of 17% to $49.7M (expense), Stock-based Compensation in SGA increase of 6% to $54.9M (expense), Other income (expense).

Equity composition

Common Stock, $0.0001 Par, 07/14, auth. 120M shares,. 24,961,926 issd,. Insiders owns approx. 20.03%.

Industry: Bio Therapeutic Drugs

215 1st St
CAMBRIDGE
MASSACHUSETTS 02142
US

Income Statement

  • Annual
  • Quarterly

News

Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

18:44, 1 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

People also watch

Gold

2,084.36 Price
+0.120% 1D Chg, %
Long position overnight fee -0.0191%
Short position overnight fee 0.0108%
Overnight fee time 22:00 (UTC)
Spread 0.31

XRP/USD

0.65 Price
+2.000% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

US100

18,323.10 Price
+0.250% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Oil - Crude

79.81 Price
+0.390% 1D Chg, %
Long position overnight fee 0.0265%
Short position overnight fee -0.0484%
Overnight fee time 22:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading